Is a differentiated care model needed for patients with TB? A cohort analysis of risk factors contributing to unfavourable outcomes among TB patients in two states in South India.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
24 Jul 2020
Historique:
received: 06 02 2020
accepted: 14 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 15 12 2020
Statut: epublish

Résumé

TB is a preventable and treatable disease. Yet, successful treatment outcomes at desired levels are elusive in many national TB programs, including India. We aim to identify risk factors for unfavourable outcomes to TB treatment, in order to subsequently design a care model that would improve treatment outcomes among these at-risk patients. We conducted a cohort analysis among TB patients who had been recently initiated on treatment. The study was part of the internal program evaluation of a USAID-THALI project, implemented in select towns/cities of Karnataka and Telangana, south India. Community Health Workers (CHWs) under the project, used a pre-designed tool to assess TB patients for potential risks of an unfavourable outcome. CHWs followed up this cohort of patients until treatment outcomes were declared. We extracted treatment outcomes from patient's follow-up data and from the Nikshay portal. The specific cohort of patients included in our study were those whose risk was assessed during July and September, 2018, subsequent to conceptualisation, tool finalisation and CHW training. We used bivariate and multivariate logistic regression to assess each of the individual and combined risks against unfavourable outcomes; death alone, or death, lost to follow up and treatment failure, combined as 'unfavourable outcome'. A significantly higher likelihood of death and experiencing unfavourable outcome was observed for individuals having more than one risk (AOR: 4.19; 95% CI: 2.47-7.11 for death; AOR 2.21; 95% CI: 1.56-3.12 for unfavourable outcome) or only one risk (AOR: 3.28; 95% CI: 2.11-5.10 for death; AOR 1.71; 95% CI: 1.29-2.26 for unfavourable outcome) as compared to TB patients with no identified risk. Male, a lower education status, an initial weight below the national median weight, co-existing HIV, previous history of treatment, drug-resistant TB, and regular alcohol use had significantly higher odds of death and unfavourable outcome, while age > 60 was only associated with higher odds of death. A rapid risk assessment at treatment initiation can identify factors that are associated with unfavourable outcomes. TB programs could intensify care and support to these patients, in order to optimise treatment outcomes among TB patients.

Sections du résumé

BACKGROUND BACKGROUND
TB is a preventable and treatable disease. Yet, successful treatment outcomes at desired levels are elusive in many national TB programs, including India. We aim to identify risk factors for unfavourable outcomes to TB treatment, in order to subsequently design a care model that would improve treatment outcomes among these at-risk patients.
METHODS METHODS
We conducted a cohort analysis among TB patients who had been recently initiated on treatment. The study was part of the internal program evaluation of a USAID-THALI project, implemented in select towns/cities of Karnataka and Telangana, south India. Community Health Workers (CHWs) under the project, used a pre-designed tool to assess TB patients for potential risks of an unfavourable outcome. CHWs followed up this cohort of patients until treatment outcomes were declared. We extracted treatment outcomes from patient's follow-up data and from the Nikshay portal. The specific cohort of patients included in our study were those whose risk was assessed during July and September, 2018, subsequent to conceptualisation, tool finalisation and CHW training. We used bivariate and multivariate logistic regression to assess each of the individual and combined risks against unfavourable outcomes; death alone, or death, lost to follow up and treatment failure, combined as 'unfavourable outcome'.
RESULTS RESULTS
A significantly higher likelihood of death and experiencing unfavourable outcome was observed for individuals having more than one risk (AOR: 4.19; 95% CI: 2.47-7.11 for death; AOR 2.21; 95% CI: 1.56-3.12 for unfavourable outcome) or only one risk (AOR: 3.28; 95% CI: 2.11-5.10 for death; AOR 1.71; 95% CI: 1.29-2.26 for unfavourable outcome) as compared to TB patients with no identified risk. Male, a lower education status, an initial weight below the national median weight, co-existing HIV, previous history of treatment, drug-resistant TB, and regular alcohol use had significantly higher odds of death and unfavourable outcome, while age > 60 was only associated with higher odds of death.
CONCLUSION CONCLUSIONS
A rapid risk assessment at treatment initiation can identify factors that are associated with unfavourable outcomes. TB programs could intensify care and support to these patients, in order to optimise treatment outcomes among TB patients.

Identifiants

pubmed: 32709228
doi: 10.1186/s12889-020-09257-5
pii: 10.1186/s12889-020-09257-5
pmc: PMC7379762
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1158

Subventions

Organisme : United States Agency for International Development
ID : AID-386-A-16-00005

Références

PLoS One. 2015 Dec 15;10(12):e0144244
pubmed: 26669737
PLoS One. 2015 Aug 24;10(8):e0135802
pubmed: 26301748
Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):853-857
pubmed: 27867891
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28242663
BMC Med. 2011 Jul 01;9:81
pubmed: 21722362
Int J Infect Dis. 2017 Jan;54:95-102
pubmed: 27894985
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21644
pubmed: 28770589
Int J Infect Dis. 2015 Mar;32:135-7
pubmed: 25809769
J Infect Public Health. 2017 Sep - Oct;10(5):527-533
pubmed: 28189508

Auteurs

Reynold Washington (R)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.
Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
St John's Research Institute, Bengaluru, India.

Rajaram Subramanian Potty (RS)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India. rajara999@gmail.com.

A Rajesham (A)

Office of the Joint Director (TB), Commissionerate of Health and Family Welfare, Hyderabad, Telangana, India.

T Seenappa (T)

Office of the Joint Director (TB), Lady Willingdon State TB Centre, Bengaluru, Karnataka, India.

Anil Singarajipura (A)

Office of the Joint Director (TB), Lady Willingdon State TB Centre, Bengaluru, Karnataka, India.

Reuben Swamickan (R)

Tuberculosis and Infectious Diseases Division, USAID/India, New Delhi, India.

Amar Shah (A)

Tuberculosis and Infectious Diseases Division, USAID/India, New Delhi, India.

K H Prakash (KH)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.

Arin Kar (A)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.

Karthikeyan Kumaraswamy (K)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.

B S Prarthana (BS)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.

Bala Krishna Maryala (BK)

TB Alert India, Hyderabad, India.

J Sushma (J)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.

Ramesh Dasari (R)

TB Alert India, Hyderabad, India.

Bharath Shetty (B)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.

Vikas Panibatla (V)

TB Alert India, Hyderabad, India.

H L Mohan (HL)

Karnataka Health Promotion Trust, IT Park, Rajajinagar Industrial Area, Behind KSSIDC Admin. Office, Rajajinagar, Bengaluru, Karnataka, 560044, India.

Marissa Becker (M)

Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH